We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 45.50 | 3.35% | 1,402.00 | 1,401.50 | 1,402.50 | 1,403.50 | 1,365.00 | 1,365.00 | 9,366,211 | 16:29:59 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1889 | 11.79 | 56.23B |
From Jan 2020 to Jan 2025
By Matt Grossman
GlaxoSmithKline PLC and Vir Biotechnology Inc. have reached an agreement to supply Singapore's government with sotrovimab, an investigational single-dose antibody treatment for Covid-19
The treatment is for people with Covid-19 who don't require supplemental oxygen and who are at risk of progressing to severe Covid-19. GSK Singapore has submitted an application for interim authorization for the drug to Singapore's health authority.
A Phase 3 trial of the drug was stopped early by its data-monitoring committee because of strong evidence of efficacy, the companies said.
In May, the U.S. Food and Drug Administration authorized the drug for emergency use.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
June 30, 2021 06:40 ET (10:40 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
